Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2015 07:30 ET | Source: Viking Therapeutics

Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator (SARM), for Acute Hip Fracture

SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or...
August 13, 2015 07:30 ET | Source: Viking Therapeutics

Viking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

Phase 2 Clinical Studies to Begin in Acute Hip Fracture and Hypercholesterolemia/Fatty Liver Disease Completes $22.3 Million IPO SAN DIEGO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Viking...
July 29, 2015 07:30 ET | Source: Viking Therapeutics

Viking Therapeutics to Conduct Phase 2 Trial of VK2809 in Patients With Cholesterolemia and Fatty Liver Disease

SAN DIEGO, July 29, 2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or...